Anti-2,2,7-trimethylguanosine (m3G/TMG) mAb
Monoclonal Antibody of 200 µl targeting 2,2,7-trimethylguanosine (m3G/TMG) for IP, IC
Target | 2,2,7-trimethylguanosine |
---|---|
Product Type | Antibody |
Application | ICC, IP |
Clonality | Monoclonal |
Conjugate | Unlabeled |
Isotype | IgG2a ĸ |
Immunogen | Carrier protein-conjugated trimethylguanosine (m3G/TMG) |
Host Species | Mouse |
Formulation | PBS containing 50% Glycerol (pH 7.2). No preservative is contained |
Research Area | Epigenetics |
Description/Background | Small nuclear RNA (snRNA) is known to be involved in pre-mRNA splicing as an RNA component of snRNP. 2,2,7-trimethylated guanosine (m3G/TMG) is a modified nucleoside at the 5’-cap site of U snRNAs except for U6 snRNA. Shortly after transcription, 7-methylguanosine (m7G), called cap structure, is added to 5’-end of newly synthesized U snRNA and m7G-capped U snRNA is exported to the cytoplasm. The m7G-cap is converted to m3G-cap, which is a hypermethylated structure of 5’-end, by cytoplasmic catalytic protein TSG1 and the m3G-capped U snRNA forms snRNP with Sm proteins in the cytoplasm, followed by entry into the nucleus. The m3G-capped snRNP plays a role in regulation of pre-mRNA splicing as a part of spliceosome in nucleus. It is also reported that U3 and U8 snoRNA, localized to Cajal body during RNP biogenesis, possess m3G-cap structure. |
Storage Temperature | -20°C |
Protocols | ICC, IP |
Clone Number | 235-1 |
Concentration | 1 mg/mL |
Regulatory Statement | For Research Use Only. Not for use in diagnostic procedures. |